Bawa / Szebeni / Webster Immune Effects of Biopharmaceuticals and Nanomedicines

1. Auflage 2018
ISBN: 978-1-351-39978-4
Verlag: Taylor & Francis
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 1038 Seiten

Reihe: Pan Stanford Series on Nanomedicine

The enormous advances in the immunology of biotherapeutics and nanomedicines in the past two decades have necessitated an authoritative and comprehensive reference that can be relied upon by immunologists, biomedical researchers, physicians, pharmaceutical and formulation scientists, clinicians, regulatory personnel, technology transfer officers, venture capitalists, and policy makers alike. This book provides a broad survey of various interconnected topics, all accomplished in a user-friendly format. The chapters are devoted to the immune stimulatory and suppressive effects of antibodies, peptides and other biopharmaceuticals, drug carrier liposomes, micelles, polymers, polymeric vesicles, dendrimers, carbon nanotubes, and other nanomedicines (with and without surface targeting ligands). The text discusses the state of the art in nanoparticle-formulated therapeutic and preventive vaccines along with their potential molecular mechanisms underlying immunogenicity. The latter phenomenon is addressed as an adverse effect of monoclonal antibody–based biopharmaceuticals and nanomedicines. Yet another adverse immune effect of monoclonals and nanomedicines, complement activation-related pseudoallergy (CARPA), is discussed in unprecedented detail in terms of occurrence, prediction, prevention, and mechanism. The range of the contributing authors accurately reflects the diverse and rapidly evolving fields of biotherapeutics, nanomedicines, nanoimmunology, and nanotoxicology. The book’s multidisciplinary and in-depth approach makes it a standard reference in this expansive and interdisciplinary field.

Zielgruppe

Professionals in the public and private sectors involved in toxicology, immunology, medicine, nanotechnology, biomedical research, biotechnology, drug development, regulatory science and governmental affairs; academic researchers and scientists, professors, postdoctoral fellows, graduate and undergraduate students, physicians, engineers, patent lawyers, regulatory personnel, pharmaceutical and biotechnology industry personnel, technology transfer officers, business managers, venture capitalists and policy makers.

Autoren/Hrsg.

Bawa, Raj

Szebeni, Janos

Webster, Thomas J

Webster, Thomas

Audette, Gerald F.

Fachgebiete

• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie Medizinische Biotechnologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie

Inhaltsverzeichnis

Proteins as Medicines: The Era of Biologics

Raj Bawa, János Szebeni, Thomas J. Webster, and Gerald F. Audette

Immunological Issues with Medicines of Nano Size: The Price of Dimension Paradox

János Szebeni and Raj Bawa

Immunotherapy and Vaccines

Johanna Poecheim and Gerrit Borchard

Emerging Trends in Delivery of Novel Vaccine Formulations

Trinh Phuong Vo, Rikhav P. Gala, Thripthy Chandran, Sucheta D’Sa, and Ruhi V. Ubale

Current Understanding of Interactions between Nanoparticles and the Immune System

Marina A. Dobrovolskaia, Michael Shurin, and Anna A. Shvedova

Auto-antibodies as Biomarkers for Disease Diagnosis

Angelika Lueking, Heike Göhler, and Peter Schulz-Knappe

The Accelerated Blood Clearance Phenomenon of PEGylated Nanocarriers

Amr S. Abu Lila and Tatsuhiro Ishida

Anti-PEG Immunity Against PEGylated Therapeutics

Amr S. Abu Lila and Tatsuhiro Ishida

Complement Activation: Challenges to Nanomedicine Development

Dennis E. Hourcade, Christine T. N. Pham, and Gregory M. Lanza

Intravenous Immunoglobulin at the Borderline of Nanomedicines and Biologicals: Antithrombogenic Effect via Complement Attenuation

Milan Basta

Lessons Learned from the Porcine CARPA Model: Constant and Variable Responses to Different Nanomedicines and Administration Protocols

Rudolf Urbanics, Péter Bedocs, and János Szebeni

Blood Cell Changes in Complement Activation-Related Pseudoallergy: Intertwining of Cellular and Humoral Interactions

Zsófia Patkó and János Szebeni

Immune Reactions in the Delivery of RNA Interference-Based Therapeutics: Mechanisms and Opportunities

Kaushik Thanki, Emily Falkenberg, Monique Gangloff, and Camilla Foged

Lipid Nanoparticles Technology Induced Immunomodulatory Effects of siRNA

Ranjita Shegokar and Prabhat Mishra

Nanovaccines against Intracellular Pathogens Using Coxiella burnetii as a Model Organism

Erin J. van Schaik, Anthony E. Gregory, Gerald F. Audette, and James E. Samuel

Immunogenicity Assessment for Therapeutic Protein Products

FDA

Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products: Guidance for Industry

FDA

The "Sentinel": A Nanomedical Strategy for Radical Immune System Enhancement

Frank Boehm and Angelika Domschke

Immunotherapy for Gliomas and Other Intracranial Malignancies

Mario Ganau, Gianfranco K. I. Ligarotti, Salvatore Chibbaro, and Andrea Soddu

Liposome-Induced Complement Activation-Related Pseudoallergy

Amr S. Abu Lila, Janos Szebeni, and Tatsuhiro Ishida

Über Autor(innen)

Raj Bawa, MS, PhD, is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm founded in 2002 and based in Ashburn, Virginia. He is an inventor, entrepreneur, professor, and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has extensive expertise in nanotechnology, pharmaceutical sciences, biotechnology, drug delivery, and biodefense-related scientific, FDA regulatory and patent law issues. Since 1999, he has held various adjunct faculty positions at Rensselaer Polytechnic Institute in Troy, New York, where he is currently an adjunct professor of biological sciences. He obtained his doctoral degree in three years (biophysics/biochemistry) from Rensselaer Polytechnic Institute. Since 2004, he has been an adjunct professor of natural and applied sciences at NVCC in Annandale, Virginia. He has been a scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel, since 2012. In the past, he has served as a principal investigator of National Cancer Institute SBIRs and reviewer for both the National Institutes of Health and the National Science Foundation. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner (6 years), acting supervisory patent examiner, and Patent Academy instructor. He is a life member of Sigma Xi and co-chair of the Nanotech Committee of the American Bar Association. He has authored over 100 publications, coedited three books, presented or chaired at over 200 conferences worldwide and serves on the editorial boards of 10 peer-reviewed journals, including associate editor of Nanomedicine (Elsevier) and coeditor-in-chief of the Journal of Interdisciplinary Nanomedicine (Wiley). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the Undersecretary of Commerce, Washington, DC (2001); Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).